Savara Inc. (SVRA)
Automate Your Wheel Strategy on SVRA
With Tiblio's Option Bot, you can configure your own wheel strategy including SVRA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SVRA
- Rev/Share 0.0013
- Book/Share 0.684
- PB 3.0262
- Debt/Equity 0.1997
- CurrentRatio 14.9138
- ROIC -0.6152
- MktCap 357772590.0
- FreeCF/Share -0.4425
- PFCF -3.7404
- PE -4.379
- Debt/Assets 0.156
- DivYield 0
- ROE -0.6588
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | SVRA | H.C. Wainwright | Buy | Neutral | -- | $2 | May 29, 2025 |
| Initiation | SVRA | Wells Fargo | -- | Overweight | -- | $8 | Dec. 20, 2024 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
Published: June 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Savara Inc.("Savara" or the "Company") (NASDAQ:SVRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Savara Inc.("Savara" or the "Company") (NASDAQ:SVRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Savara Inc.("Savara" or the "Company") (NASDAQ:SVRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Savara Inc.("Savara" or the "Company") (NASDAQ:SVRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Savara Inc.("Savara" or the "Company") (NASDAQ:SVRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. - SVRA
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Did Savara Inc. (SVRA) Mislead Investors? Levi & Korsinsky Investigates
Published: May 30, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Savara Inc. ("Savara Inc.") (NASDAQ:SVRA) concerning possible violations of federal securities laws. On May 27, 2025, the company announced that the FDA issued a Refusal to File letter for its Biologics License Application for Molbreevi, its lead drug candidate for autoimmune PAP.
Read More
Levi & Korsinsky Launches Fraud Investigation on Behalf of Savara Inc. (SVRA) Shareholders
Published: May 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Savara Inc. ("Savara Inc.") (NASDAQ:SVRA) concerning possible violations of federal securities laws. On May 27, 2025, the company announced that the FDA issued a Refusal to File letter for its Biologics License Application for Molbreevi, its lead drug candidate for autoimmune PAP.
Read More
INVESTOR ALERT: Investigation of Savara Inc. (SVRA) Announced by Holzer & Holzer, LLC
Published: May 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, May 27, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) complied with federal securities laws. On May 27, 2025, Savara announced that it had received a refusal to file letter from the FDA for the Biologics License Application of MOLBREEVI as a therapy to treat patients with autoimmune pulmonary alveolar proteinosis. Following this news, the price of the Company's stock dropped.
Read More
Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?
Published: May 27, 2025 by: Benzinga
Sentiment: Negative
Savara Inc. SVRA on Tuesday announced that it received a U.S. Food And Drug Administration (FDA) refusal To File (RTF)) letter regarding the Biologic license application (BLA) for Molbreevi, a therapy for treating patients with autoimmune Pulmonary Alveolar Proteinosis (PAP).
Read More
BREAKING: Savara Shares Down Over 30%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses
Published: May 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Block & Leviton is investigating Savara Inc. (Nasdaq: SVRA) for potential securities law violations. Investors who lost money should contact the firm.
Read More
Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025
Published: May 18, 2025 by: Business Wire
Sentiment: Neutral
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced new data in two poster presentations at the ATS International Conference 2025. Data presented were from the Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP and demonstrated that molgramostim reduces surfactant burden and improves health-related quality of life outcomes in patients with aPAP. ATS 2025 Posters Poster Ti.
Read More
Savara: Make-It-Or-Break-It Molbreevi BLA Filing
Published: April 21, 2025 by: Seeking Alpha
Sentiment: Positive
Savara, Inc. focuses exclusively on developing its sole therapeutic product, MOLBREEVI. Its investment thesis highlights the potential of MOLBREEVI to address unmet medical needs in autoimmune pulmonary alveolar proteinosis (aPAP). Rating justification: Strong clinical data, multiple FDA designations and a clear path to regulatory approval make Savara a compelling investment opportunity.
Read More
About Savara Inc. (SVRA)
- IPO Date 2017-04-28
- Website https://www.savarapharma.com
- Industry Biotechnology
- CEO Mr. Matthew Pauls J.D., M.B.A.
- Employees 59